Bioplastics resin maker Metabolix is losing its commercial alliance with agricultural company Archer Daniels Midland (ADM). ADM said the venture is not delivering sufficient results, and that financial projections for the business are too uncertain.
As a result, Telles, the US-based sales and marketing alliance formed to commercialize Mirel polyhydroxyalkanoate resin, will be dissolved.
Metabolix said it is conducting a strategic review of its business plans for 2012, and that it will restructure its bioplastics business and downsize its operations.
"Clearly, we are disappointed by ADM's decision to withdraw from Telles. While this is a setback, we remain committed to successfully commercialising PHA bioplastics. Over the past few years, we now have proven the technology at industrial scale and believe that we now have the opportunity to launch this business with a different business model," said Metabolix CEO Richard Eno, in a news release.
Metabolix reported a loss of $29.2m (€22.8m) for the nine month period that ended 30 September, on sales of $567,000 (€442,280).
The news may be surprising — given plastics industry interest in biopolymers. However, there has been more activity recently in the sector of the bioplastics market that involves making conventional resins made from plant materials, including polyethylene, PET and polypropylene. Corn-based polymers like PHA have been receiving less attention.
A recent report from Ceresana Research, for example, predicted that the global bioplastics market will grow an average of 17.8% annually to reach $2.8bn (€2.2bn) in sales in 2018 — but much of the growth will come from non-biodegradable bioplastics.
Telles may be a well known brand, but the company's is still in start-up mode. Last year the company started Mirel production at a plant in Iowa, the US. According to ADM, there are about 90 full-time ADM Polymer employees in Clinton, plus a small number elsewhere that support Telles sales efforts in Europe. The company will evaluate the impact on staffing of its decision to exit the joint venture.
According to a news release, ADM Polymer may provide PHA fermentation services for Metabolix during a three-year period following termination of the agreement.
"We have analysed our business portfolio, identifying areas that are not delivering sufficient results now or are not expected to deliver sufficient results within a reasonable timeframe,” said Mark Bemis, president of ADM's corn division, in a release. “We have had a good working relationship with Metabolix, and the fermentation technology performed well at our facility. Unfortunately, uncertainty around projected capital and production costs, combined with the rate of market adoption, led to projected financial returns for ADM that are too uncertain. Therefore, we have decided to exit the business as permitted by the commercial alliance agreement with Metabolix.”
ADM said it is evaluating other uses for its fermentation plant in Clinton. ADM said it will take a one-time pretax charge of $300-360m (€234-280m) in the second quarter as a result of its decision.
Metabolix said it plans to continue to focus on development of renewable industrial chemicals, and that it will "retain a core team in its bioplastics group to provide continuity with the technology and market".